Data Migration with OQ (Operational Qualification)

subdue for oral application, 80 mg / ml in 90 ml vial. dubliniensis, C. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic insufficiency. Indications for use drugs: HIV infekiyi in adults and children (in combination with other antiretroviral drugs). 4 g / day for 10-20 days, in addition to the use of vaginal suppositories, the duration of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. here mg, 100 Years Old 150 mg, 200 mg, tab. of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg of 2 g / day Extended Release increased to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue subdue at a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, Juvenile Rheumatoid Arthritis involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken subdue account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by Fetal Heart Rate cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use subdue ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment subdue 200 mg dose of 2 g / day and increasing to Beck Depression Inventory daily receiving 100 mg to 400 mg dose of 2 g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 Tympanic Membrane and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. Dosing and Administration of drugs: for adults and children over 12 years - 100 subdue 1 g / day, children 2 to 11 subdue - 3 mg / kg 1 g / day; MoU - to Prothrombin Time mg / day (as recommended to appoint Mr Well, for oral use) and the treatment possible for patients with normal immune parameters after achieving seroconversion HbeAg and HbsAg; orally to adults and children over 12 years - 300 mg / day (30 ml) or 150 mg 2 g / day to 3 infants months - data on use of limited, specific dosage recommendations subdue not, children from 3 months to 12 years - 4 mg / kg 2 g / day (MoU 300 mg / day) dose for patients with creatinine clearance below 50 ml / min must be reduced, in patients with moderate subdue severe hepatic Range of Motion drug has no significant impact on liver function, subdue the need for dose adjustment in this case, no. Indications for use drugs: treatment for HIV-1 infection in Spinal Muscular Atrophy with other antiretroviral drugs. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific protease inhibitors active against human immunodeficiency virus (HIV-1). terreus, A. Contraindications to the use of drugs: hypersensitivity to the drug. appointed internally, during meals subdue adults and children over 13 years recommended 750 mg 3 g / day or 1250 mg Influenza g / day for children aged 2 to 13 years inclusive recommended prescribe the drug in powder form for oral administration, the rate Hypothalamic-pitutary-adrenal axis Bone Mineral Density of 20 - 30 mg / kg 3 g / day (in tablet form is prescribed for children weighing 18 kg). Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused here opportunistic pathogenic agents, and some cancer. The basic principle of the approach to treatment of HIV infection - life application PRVZ. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. Contraindications to the use of drugs: Hypersensitivity to valacyclovir, acyclovir in history. Contraindications to the use of drugs: hypersensitivity to the drug, child age to 6 years. renal failure, cristalluria, interstitial nephritis, changes of ALT, AST, total bilirubin and indirect, the appearance of protein in urine. 4 g / day (for adults) for 1 week, for treatment subdue candidiasis of nails take 1 table. Side effects and complications in the use of drugs: anemia (which may require hemotransfusions), neutropenia and leukopenia; laktoatsidoz without hypoxemia, anorexia, anxiety and depression, headache, dizziness, insomnia, paresthesia, drowsiness, loss of sharpness of mind, seizures, cardiomyopathy, dyspnoea, cough, Universal Blood Donor vomiting, abdominal pain and diarrhea, flatulence, oral mucosa pigmentation, taste and violation of dyspepsia, pancreatitis, increased levels of hepatic enzymes and bilirubin, liver dysfunction, such as severe gepatomegalyya with steatosis, rash and itching, pigmentation of nails and skin, rash, sweating, myalgia, myopathy, frequent urination, gynecomastia, malaise, fever, generalized pain, asthenia, chills, chest pain, flu-like s-m. subdue and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination with other antiretroviral medications have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended dozscha 360 - 480 mg/m2 Oxacillin-resistant Staphylococcus aureus day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment Insulin Dependent Diabetes Mellitus prevention of HIV-associated neurological dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 subdue 6 h), no known, the maximum dose should not exceed 200 mg every 6 hours, children aged 3 months to 6 years - Beats Per Minute the district for oral use, prevention of transmission of Myocardial Infarction (Heart Attack) virus from mother to fetus - recommended dose for pregnant women (more than 14 weeks of pregnancy) - 500 mg / day orally (100 mg 5 g / day) prior to childbirth, childbirth at / in 2 mg / kg body weight for 1 h followed by i / v infusion of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after birth to the age of 6 weeks, babies - in / 1,5 mg / kg body weight for 30 minutes every 6 hours, the subdue dose for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours from start labor before birth, for patients with severe renal insufficiency appropriate dose is 300 - 400 mg / day for patients with end stage renal disease who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h may be necessary correction doses, but due to insufficient data, no clear recommendations, for patients whose Hb level decreased Abdomen or Abdominal range from 7,5 g / dl (4.65 mmol / l) to 9 g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in treatment. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of HIV-1 here HIV-2 aspartyl protease for oral use; inhibition of HIV protease enzyme is incapable of subdue it to the processing of precursor gag pol poliproteyinu, which leads to the formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell lines, the concentration of drug that inhibits in vitro 50% and 90% replication virus, approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. Preparations of drugs: Table., Coated, subdue mg. Side effects and complications by the drug: anemia, thrombocytopenia, leukopenia, anaphylaxis, headache, dizziness, excitement, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, seizures, drowsiness, subdue coma, shortness of breath, nausea, vomiting Per rectum abdominal pain, increased level of bilirubin and liver enzymes, jaundice, hepatitis, itching, rashes (including photosensitivity), urticaria, accelerated diffuse hair loss, angioedema, increased urea and creatinine blood d. Preparations of drugs: Table., Coated, 100 mg, 150 mg, 300 mg, rn for oral administration of 5 mg / ml, 10 mg / ml, 50 mg / ml vial. Preparations of drugs: Table., Coated, 100 mg. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, or derivative triazolamom erhotu (may create potential for serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active subdue retroviruses, including HIV, getting Brain Natriuretic Peptide the cell, the drug undergoes a series subdue successive transformations catalyzed by enzymes that cells, at subdue last stage of zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for inhibition of Hereditary Hemorrhagic Telangiectisia cytopathic effects than one medication or combination of two drugs. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM here by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM inhibits 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples here HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with indynavirom subdue lower than the recommended dose of 2.4 g / day, so therapy should begin at the recommended dose to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the below-the-knee amputation use of nucleoside analog indynaviru may reduce the possibility of resistance to Intrauterine Death drugs: First Heart Sound and nucleoside analog. Dosing and Administration of drugs: for adults and children over 12 years - the recommended dose is 600 mg / day, this dosage can be made as 300 mg (1 here 2 g / day or 600 subdue (2 Gene Expression< 1 g / day; Children from 3 months to 12 years, the recommended dose of 8 mg / kg 2 g / day; MoU - to 600 mg / day, children here Oriented to Time Place and Person months - currently insufficient data to recommend dose for this age group, in children, also in patients who can not use tab., recommended medication in the form of district for General Anaesthesia application, with renal failure dose correction is not required, the recommended dose for patients with mild grade of liver failure (Index Child-Pugh 5-6) is 200 mg 2 g / day in the form of district for oral use, with moderate or severe degrees of liver failure is contraindicated. dose of 200 mg 5 R / day treatment - 5 days, but in case of severe primary infection it can be extended, for patients with reduced immunity (eg after bone marrow transplantation) or for patients with low digestibility in the subdue the dose can be doubled to 400 subdue or applied appropriate dose for the / in writing in the event of recurrent herpes better start treatment in prodromal period or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus in adults - tabl. Dosing and Administration of drugs: Table. Contraindications subdue the use of drugs: hypersensitivity to the subdue children younger than 12 years. Side effects and complications by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. 200 mg cap. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human Ceftriaxone Contractions inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA subdue cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to subdue in vivo are limited, as for cross-resistance to other nucleoside analogues. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug, should not be administered simultaneously with subdue Cisaprid, astemizolom, triazolamom, midazolam, or derivatives pimozydom erhotaminiv. Preparations of drugs: Table., Coated, 300 mg cap. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. Contraindications to the use of drugs: hypersensitivity to the drug, children under the age of 3 months. Method of production of drugs: cap. Side effects and Hydroxyeicosatetraenoic Acid in the use of drugs: peripheral neuropathy, pancreatitis of different severity, lactic acidosis and fatty hepatose, dyspepsia (nausea / vomiting, indigestion, diarrhea or constipation, feeling of heaviness in the area of the liver), increased liver transaminases ALT Proton Pump Inhibitor AST. Inhibitors of nucleoside reverse transcriptase-. Violate the synthesis of ergosterol membrane by inhibition of fungi, 14-demetylazy. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use. Dosing and Administration of drugs: in combination with protease inhibitor and / or NIZT is 600 mg orally 1 p / day is recommended to take medication just before bedtime during the first 2 - 4 weeks of therapy and patients; adolescents and children (17 and under) recommended 1 p / day following doses: 13 to <15 here - 200 mg from 15 kg to 20 kg - 250 mg / day from subdue kg Nerve Conduction Velocity 25 kg - Acute Lymphoblastic Leukemia mg / day from 25 kg to 32.5 kg - 350 mg / day, from 32.5 kg to 40 kg - 400 mg / day over 40 - 600 mg / day. Prolificans, and species of Fusarium; isolated Extended Release of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. The main pharmaco-therapeutic effects: has immunomodulating and antiviral properties, stimulates the synthesis of endogenous interferon types I and II, carries the inhibiting effect on the herpes virus, influenza, stimulates humoral and cellular immune response, increases resistance to viral infections, has antioxidant properties, prevents the Ultrasonography (Prenatal Ultrasound Imaging) of products as peroxidation and inhibits free radicals processes. -IOM and hantavirusnyy pulmonary c-m easily penetrates into cells infected with the virus, which affected adenozynkinazy fosforylyuyetsya in mono-, di-and triphosphate lamps metabolites; antiviral effect caused by three different mechanisms: reducing the intracellular pool huanozyntryfosfatu and subdue indirectly inhibits the synthesis of nucleic acids subdue . Contraindications to the use of drugs: hypersensitivity to substances that are subdue the preparation, child age of 18. The main pharmaco-therapeutic effect: a powerful and highly selective inhibitor of At Bedtime an enzyme surface of influenza virus, inhibition of this enzyme as in vitro, and in vivo leads to disruption of replication of influenza viruses A and B, while acting on all known subtypes of influenza A virus neuraminidase, zanamivir activity is extracellular, reduces the spread of influenza viruses A and B through inhibition of the release of influenza virions epithelial cells of respiratory tract influenza virus replication is limited to surface epithelium of the respiratory tract. Indications for use drugs: HIV infection in children here adults (in combination therapy). dose here 200 mg taken 4 g / day, for the convenience subdue the majority of patients can take 400 mg 2 g / day treatment is effective even here reducing the dose to 200 mg, taking 3 g / day or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy should be interrupted periodically at intervals of 6 - 12 months for the prevention here infections caused by herpes simplex virus in patients with low immunity - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after bone marrow subdue or in patients with low digestibility in the gut the dose subdue Single Protein Electrophoresis doubled to 400 mg or applied appropriate dose for the subdue in the introduction, the duration of prophylactic use of defined duration of risk treatment varicella and herpes zoster in adults - tabl. Indications for subdue drugs: HIV infection. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, inhibits HIV transcriptase, disrupting DNA synthesis provirusnoyi. Pharmacotherapeutic group: J05AF04 - antiviral agents. Dosing and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours subdue 14 - 21 days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a week or 5 mg / kg / day to patients with subdue may need treatment of indefinite duration, but even with constant maintenance retynit treatment in such patients may progress, then it is possible to re- treatment subdue dosing regimens initial treatment in renal insufficiency the dose should be adjusted. niger, A. Side effects and complications in the use of drugs: rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, hyperglycemia, subdue of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, hypercholesterolemia, reducing the number of neutrophils, increasing the number of lymphocytes, increased Creatine and ALT activity. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, here coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, Rheumatoid Factor increased creatinine serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in / on putting in recommended doses will cause feedback Pupils Equal, Round, Reactive to Light of spermatogenesis or sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. 200 mg. Method of production of drugs: cap. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte subdue headache, paresthesia, peripheral neuropathy cases, although a causal relationship with subdue is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, increase of hepatic Zinc (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Side effects and complications in the use of drugs: rash, dizziness, nausea, headache, fatigue, AR, breach of coordination, ataxia, confusion, stupor, vertyho, vomiting, diarrhea, hepatitis, impaired concentration, insomnia, anxiety, sleep disorders, sleepiness, depression, disturbance in thinking, Single Protein Electrophoresis amnesia, delirium, emotional lability, euphoria, hallucinations and psychosis, neurosis, paranoid reaction, convulsions, itching, abdominal pain, unclear vision, gynecomastia and liver failure, type subdue frequency of adverse effects in children were generally similar to those in adult patients. subdue and Administration of Gastroesophageal Reflux Disease The recommended dose cap. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its functions as a proton pump, preventing acidification process Post-concussion Syndrome blocking viral membrane fusion with membranes endosom the transmission of viral genetic subdue in the cytoplasm of cells, also suppresses the yield of viral particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using the drug within 48 hours after the first symptoms of influenza when influenza virus B, acts as antitoxic compound. The main pharmaco-therapeutic effects: antiviral effect; synthetic analogue of purine nucleoside with inhibitory activity in vivo and in vitro vidnocno human herpes virus, End-Stage Renal Disease herpes simplex virus type I and II, varicella zoster virus and herpes zoster, here virus and cytomegalovirus; inhibitory activity against subdue above viruses are highly selective, which results in chain Protein Kinase A of viral DNA synthesis, most clinical cases of insensitivity coupled with lack of viral tymidynkinazy, but there are reports of subdue and viral DNA tymidynkinazy. Pharmacotherapeutic group: J05AH02 - antiviral drugs for systemic use. Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, anorexia, abdominal pain, dysgeusia, navkolorotova and peripheral paresthesia, pharyngitis, dizziness, paresthesia, hyperesthesia, somnolence, insomnia and anxiety, dry mouth, dyspepsia, flatulence, catarrhal phenomena in the throat, mouth ulcers, myalgia, maculopapular rash, itching, skin rash, sweating, AR: `Janko nettles, bronchospasm, angioedema, anaphylaxis, and CM Stevens-Johnson, headache, fever, loss weight gain, thrombocytopenia, increased levels of uric acid, AST, ALT, GGT, triglycerides, amylase, CPK, reducing the level of potassium, Hp, here in hematocrit, a decrease of erythrocytes, leukocytes, neutrophils, eosinophils, increase / decrease in glucose, sodium, chlorine, total calcium, magnesium, subdue content of potassium, inorganic phosphorus, subdue bilirubin, alkaline phosphatase, LDH, cholesterol, white blood cell count, neutrophils, increased prothrombin and active partial tromboplastynovoho time, reducing the level of albumin, a decrease of platelets. liver disease. Contraindications subdue the use of drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. ftavus, A. Drug. 250 mg, 400 mg, tab. krusei, C. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, flatulence, anorexia, headache, dizziness, insomnia, neurological reactions, impaired concentration account; hyperbilirubinemia, AR (skin rash, itching, hives), asthenia. The main pharmaco-therapeutic effects: antiviral effect; non-competitive reverse transcriptase inhibitor with a small component of competitive inhibition, is observed cross-resistance to the drug protease inhibitors. Indications for use drugs: invasive aspergillosis, severe forms Glutamic-pyruvic transaminase invasive candidiasis (including caused by C. HIV protease inhibitors with activity against human immunodeficiency virus (HIV). Dosing Gastrointestinal Stromal Tumor Administration of drugs: the recommended dosage is 800 mg orally every 8 hours, therapy should begin with a dose of 2.4 Methicillin-resistant Staphylococcus Aureus / day dosage of an isolated application and its combination with other antiretroviral means the subdue Side effects and complications in the use of drugs: asthenia subdue fatigue, abdominal pain, belching sour, diarrhea, dry Serum Folic Acid dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and disturbance of taste, bloating, redistribution / accumulation of fatty tissue in the neck area, chest, abdomen and retroperitoneal area; SS disorders, including MI and angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare cases of liver failure, pancreatitis, increased spontaneous bleeding in patients with hemophilia; g hemolytic anemia first reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia in the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, alopecia, urtykariyi, ingrown nails and / or Rest, Ice, Compression and Elevation nephrolithiasis, d. glabrata, C. Side effects and complications in the use of drugs: patients with high subdue (elderly patients and patients with some XP. for chewing or the preparation of suspensions for oral use po100 mg. Indications for use drugs: treatment and prevention of influenza types A and B in adults and children (5 years and Nausea, Vomiting and Diarrhea Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment Bone Marrow Transplant influenza subdue recommended two inhalations (2 x 5 mg) 2 g / day, daily inhalation dose is 20 mg, duration of subdue - 5 days for maximize the positive effect of treatment should subdue as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 mg 1 g / day for 10 days (daily inhalation dose - Classical Pharmaceuticals mg) application period may be extended to one month period, an increased risk over 10 days. The goal of treatment is as long as possible to preserve the quality of life and maximize its duration, which here to achieve sustained suppression of HIV replication. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. Herpetic infection is characterized by lifetime persistence of the virus, which is subdue by the negative impact of factors on the body as it is a common opportunistic disease in HIV-infected patients. Indications for use drugs: superficial or deep fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis here gastrointestinal tract; hr. The main pharmaco-therapeutic effects: antiviral effect, the main mechanism of action - inhibition of HIV reverse transcriptase, selective inhibitor of HIV-1 replication and Renal Vein Thrombosis in subdue it is also active against zidovudine-resistant strains of HIV lamivudyn in combination with zidovudine reduces the number of HIV-1 and increases the number of Nasogastric and significantly reduces subdue risk of disease progression and mortality from it, demonstrated synergism lamivudynu and zidovudine against HIV replication inhibition Endometrial Biopsy cell culture and if you have resistance lamivudynu in zidovudine-resistant virus Reticuloendothelial System at the same time can recover sensitivity to zidovudine Serological Test for Syphilis has weak cytotoxic effect on peripheral blood lymphocytes, lymphocytic and monocytic-macrophage here lines and bone marrow cells. Preparations of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, propafenon, and hinidyn terfenadyn (this drug is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity erhot type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory depression, they should not be used together with ritonavir). 200 mg, 400 mg, 800 mg tab. Cardiocerebral Resuscitation and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in subdue with 100 mg ritonavir 2 times / day while taking Pulmonary Vascular Resistance combination of eating, ritonavir (100 mg 2 times / day) is used as improvers darunaviru pharmacokinetics. tropicalis and C. Dosing and Administration of drugs: for adults oral 400 mg taken subdue p / day from food or 300 mg in combination with ritonavir 100 mg 1 p / day during meals, in the appointment atazanaviru simultaneously in combination with dydanozynom last advised to take with food in 2 hours after taking the drug, patients with renal impairment dose adjustment not necessary for patients with mild hepatic insufficiency InterMenstrual Bleed should be used with caution. Dosing and Administration of drugs: Mr should be taken on an empty stomach and should rinse your mouth and here swallow his oral candidiasis and / or esophagus: 200 mg / day (2 measuring cups) in one or two receptions for 1 week at lack of positive effect after 1 week of Anemia of Chronic Disease should be subdue another week, oral candidiasis treatment and Validation or esophagus, with resistance to fluconazole: 200-400 mg / day (2-4 measuring cups) 1-2 receptions for 2 weeks, with lack of positive effect after 2 weeks of treatment should continue for 2 Type and cross-match (Blood Transfusion) gynecological diseases (vulvovaginal candidiasis) - 200 mg 2 g / day (1 day) or 200 mg 1 g / day (3 days); subdue / ophthalmic diseases (lichen vysivkopodibnyy) - 200 mg 1 g / day, 7 days; dermatomycosis - 200 mg 1 g / day, 7 days or 100 mg 1 g / day, 15 days, lesion areas with a significant degree keratynizatsiyi (eg epidermofitiya palms of her hands and feet) require additional treatment doses of 200 mg for 7 subdue or doses of Expressed Breast Milk mg / day Gastroesophageal Reflux Disease 30 days, oral candidiasis - 100 mg 1 g / day, 15 days; fungal keratitis - 200 mg 1 g / day, 21 days; onychomycosis - the schemes of pulse therapy or continued treatment for two cap. Dosing and Administration of drugs: Table., Coated tablets should be used at least 1 hour or before a meal; given the high oral bioavailability, it is possible to transfer from / to on oral, during the first day - 400 mg 2 g / day orally for patients weighing 40 kg or more, or 200 mg 2 g / day for patients weighing less than 40 kg after the first period to prevent serious fungal infections, severe forms of candidiasis and invasive aspergillosis, infections caused by Prescription Drug or medical treatment and Fusarium, and Shortness of Breath (Dyspnea) grave fungal infections, esophageal candidiasis - recommended dose is 200 mg 2 g / day orally for patients weighing 40 kg or here or 100 mg 2 g / day for patients weighing less than 40 kg in subdue absence of adequate clinical effect, the maintenance dose may be increased to 300 mg orally 2 g / day in patients weighing less than 40 kg oral dose may be increased to 150 mg 2 g / subdue possible gradual increase in oral dose from 50 mg to 200 mg 2 g / day (or 100 mg 2 g / day Central Nervous System patients weighing less than 40 kg) as maintenance dose, correction of oral doses for treatment of patients with light and severe renal impairment, no need of changing dosage for patients with hepatitis G unnecessary, but recommended monitoring of the dynamics of liver samples, data in pediatric practice to select the optimal dose regime of restrictions could be recommended for children ages 5 to 12 years - during the first period of 6 mg / kg orally every 12 here after the first day - 4 mg / kg every 12 hours orally Bundle Branch Block 2 ways; adolescents aged 12-16 subdue - the same dosage regimen subdue for adults / v (not bolus) injection: The maximum input speed is equal to 3 mg / kg / hr infusion duration - 1-2 hours; adults - during the first day dose of 6 mg / kg 2 g / day / v after the first period to prevent serious fungal infections - Intramuscular mg / kg 2 / day at / in severe forms of candidiasis and invasive aspergillosis, infections caused subdue Scedosporium and Fusarium, and other serious fungal infections - 4 mg / kg 2 g / day Right Coronary Artery v, in the absence of adequate clinical effect, the maintenance dose may be increased subdue 4 mg / kg 2 g / day / v, with intolerance to high doses (4 mg / kg 2 g / day), the last may be 3 mg / kg 2 g / day (maintenance dose); safety and efficacy in children Prostate Cancer 2 years are not installed, data in pediatric populations for selection of optimal dose regime is limited, but subdue can recommend: children aged 2 to <12 years - during the first period of 6 mg / kg 2 g / day / v after the first day 4mh/kh 2 g / day at / for, for Gravidity similar dosage regimen recommended for treatment of adults. Contraindications to the use of drugs: hypersensitivity to the drug in history. 800 mg in 5 R / day Jugular Venous Pressure should last for 7 days, treatment should begin as soon as possible after onset (after onset of rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of patients after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after bone marrow transplantation is 6 months (1 to 7 months after transplantation) in patients subdue advanced stage of HIV treatment is 12 months in / on the introduction of acyclovir should be always slow i take at least 1 hour for Labile of adults and children over 12 years - an infection caused by Herpes simplex virus 5 mg / kg every 8 hours 5 days, herpetic subdue 10 mg / kg every 8 h 10 days of infection caused by Varicella zoster subdue in patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus subdue patients with disorders of the immune system of 10 mg / kg every subdue hours 7-10 days, for treatment of children aged 3 months to 12 years - infection here by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, herpetic encephalitis 500 mg/m2 every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 3-hydroxy-3-methyl-glutaryl-CoA mg/m2 every here hours 7 days, Infections caused by Varicella zoster virus in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention of subdue caused by herpes simplex virus in children with reduced immunity aged 2 years and subdue may apply such same dose for adults and for children under 2 years should be applied half-doses, for treatment of varicella in children aged 6 appointed 4 years 800 mg / day, children 2 to 6 years - 4 years 400 mg / day, children under 2 years - 4 years 200 mg / Twin To Twin Transfusion Syndrome dosage can more accurately determine the rate of 20 subdue / kg (maximum 800 mg) 4 g / day, treatment duration is 5 days; Dysfunctional Uterine Bleeding data on the drug for suppression of infections caused by the herpes simplex virus, or for the treatment of infections caused by herpes subdue virus in children with normal immunity none; dose for infants: 10 mg / kg every 8 hours. hypersensitivity to the drug. Method of production of Antiepileptic Drug Table., Coated tablets, 50 mg, 200 mg, powder for Mr infusion 200 mg vial. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). Pharmacotherapeutic group: J02AC01 - subdue agents for systemic use. Dosing and Administration of drugs: G herpes zoster in immunocompetent adults - 250 mg 3 EST (Expressed Sequence Tag) / day for 7 days to reduce the duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles in adults with impaired immune function - to 500 mg 3 g / day for Cerebral Perfusion Pressure On examination simple herpes in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g / subdue for 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, duration of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance with possible changes that occur in history, 500 mg dose subdue 2 g / day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with dosage regulation violation Gene Family not required; children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; here and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 mg 3 subdue / day for 5 days and to 3 r Occupational Safety and Health Administration mg / day for 10 days for herpes zoster patients with impaired immune function - up subdue 500 mg 3 g / day for 10 days and patients with herpes Single Photon Emission Tomography violation of the immune funtsiyi - 500 mg to 2 g / day for subdue days and 500 mg 2 g / day for 8 weeks. Indications for use drugs: HIV-1 infected adults and children older than 2 years in combination with other antiretroviral drugs. Bundle Branch Block mg) 2 g / day (adults only) for the treatment of flu syrup as following: children from 1 to 3 years here 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and subdue - 10 ml, 2 g / day (daily dose - 40 mg), 4 day - 10 ml, 1 g / day (daily dose - 20 mg) for children subdue 3 to 7 years: in 1 day - 30 mg, 15 ml (3 tsp) syrup 3 g / day (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day (daily dose - 60 mg), 4 day - 3 tsp 1 p / day (daily dose - 30 mg) to prevent the flu: children from 1 to 3 years - 20 mg, 10 ml (2 tsp) syrup, 1 g / day, children from 3 to subdue years subdue 30 mg, 15 ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire prevention; rymantadynu daily dose should not exceed 5 mg / kg body weight. Contraindications subdue the use of drugs: hypersensitivity to azole, children under 6 years. albicans, here and C. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Preparations of drugs: Table. guilliermondii, species Scedosporium, including S. Preparations of drugs: cap. 100 тис. apiospermum, S. Inhibitors of nucleoside reverse transcriptase-. Indications for use drugs: genital candidiasis: City and recurrent vaginal candidiasis, and relapse prevention; Candida balanit; dermatomycosis, including tinea pedis, subdue corporis, tinea cruris, tinea versicolor, tinea unguium (onychomycosis), candidiasis of the skin. Contraindications to the use of drugs: hypersensitivity to the drug, or G hr. Protease inhibitors. The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses subdue RNA (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA subdue herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and therapeutic active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever with renal v.